Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
19.82
+0.05 (0.25%)
Feb 27, 2026, 3:00 PM CST
Market Cap32.35B -8.4%
Revenue (ttm)24.18B -5.4%
Net Income1.43B -26.9%
EPS0.87 -26.6%
Shares Out1.63B
PE Ratio22.68
Forward PE13.93
Dividend0.47 (2.38%)
Ex-Dividend DateAug 19, 2025
Volume11,560,840
Average Volume20,197,932
Open19.75
Previous Close19.77
Day's Range19.72 - 19.90
52-Week Range16.73 - 23.66
Beta0.51
RSI67.86
Earnings DateMar 31, 2026

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec... [Read more]

Sector Healthcare
Founded 1988
Employees 17,650
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2024, SHA:600079's revenue was 25.44 billion, an increase of 3.71% compared to the previous year's 24.52 billion. Earnings were 1.33 billion, a decrease of -37.70%.

Financial Statements